LeonaBio, Inc. last reported quarterly results on Aug 14, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): diluted EPS of -$0.80. It usually reports 37–45 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 5, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 6, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 37–45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 14, 2026
45 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
—
|
-19
-172.9%
|
-0.80
+55.1%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
—
|
-33
-260.4%
|
-1.73
+26.1%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
—
|
-7
+77.0%
|
-1.68
+77.5%
|
|
Aug 7, 2025
38 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
—
|
-7
+74.1%
|
-1.78
-154.3%
|
|
May 9, 2025
39 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
—
|
-9
+65.3%
|
-2.34
-239.1%
|
|
Feb 27, 2025
58 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
—
|
-15
+45.0%
|
-3.88
-441.4%
|
|
Nov 7, 2024
38 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
—
|
-29
+12.8%
|
-7.46
-757.5%
|
|
Aug 1, 2024
32 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- LONA (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Bothell, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1620463
- Former names
- Athira Pharma, Inc. (until Jan 8, 2026); M3 Biotechnology, Inc. (until Jan 23, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.